ERCC1 表达与卵巢癌铂类化疗敏感性的关系：一项荟萃分析。
ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis.
机构信息
Gynecology Unit II, Gansu Provincial Maternity and Child-care Hospital, Lanzhou, Gansu, China.
Department of Gynecology and Obstetrics, Affiliated Hospital of Northwest Minzu University, The Second People's Hospital of Gansu Province, Lanzhou, Gansu, China.
出版信息
Int J Biol Markers. 2020 Dec;35(4):12-19. doi: 10.1177/1724600820963396. Epub 2020 Oct 30.
OBJECTIVE
This study aimed to comprehensively investigate the correlation of ERCC1 expression and chemosensitivity of ovarian cancer.
METHODS
The literature on the relationship between the excision repair cross complementary gene 1 (ERCC1) and the chemosensitivity of ovarian cancer published in PubMed, Web of Science, EMBASE, CNKI, and the China Wanfang database from the establishment of the databases to June 2020 were searched. Chemosensitivity is evaluated by clinical effective rate (complete remission plus partial remission). Statistical analysis was carried out by using Stata 15.1 software.
RESULTS
A total of 11 articles met the inclusion criteria, consisting of 758 patients with ovarian cancer. The results showed a significant difference in chemosensitivity between the low expression group and the high expression group of ERCC1 (odds ratio 4.23; 95% confidence interval 2.96, 6.06; < 0. 01). The same result was shown in the ethnicity subgroup.
CONCLUSION
The chemosensitivity of ovarian cancer patients with a low expression of ERCC1 is better than that of patients with a high expression.
目的
本研究旨在全面探讨 ERCC1 表达与卵巢癌化疗敏感性的相关性。
方法
检索 PubMed、Web of Science、EMBASE、中国知网（CNKI）和万方数据库建库至 2020 年 6 月收录的有关 ERCC1 与卵巢癌化疗敏感性相关的文献。采用化疗有效率（完全缓解加部分缓解）评价化疗敏感性。采用 Stata15.1 软件进行统计学分析。
结果
共纳入 11 篇文献，包含 758 例卵巢癌患者。结果显示 ERCC1 低表达组与高表达组的化疗敏感性差异有统计学意义（比值比 4.23，95%置信区间 2.96~6.06；<0.01）。亚组分析结果也显示出相同的结果。
结论
ERCC1 低表达的卵巢癌患者的化疗敏感性优于 ERCC1 高表达的患者。
Zotero 插件